Commitments and Contingencies (Details Narrative) - USD ($)								1 Months Ended
	Feb. 01, 2023	Jul. 20, 2022	Jul. 18, 2022	Nov. 17, 2021	Aug. 20, 2021	Aug. 20, 2021	Jul. 28, 2021	Feb. 16, 2022
Licensing Agreement MLR1019 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt instrument, periodic payment							$ 21,800,000
Gross sales percentage							5.00%
Option purchase percentage							10.00%
Royalty gross sales percentage							2.50%
License agreement commitments description				On November 17, 2021, Melior I extended the Company’s timeline from 120 days to 180 days from the effective of the MLR-1023 Agreement for the Raise Requirement, by 180 days Adhera is in the process of completing transactions to complete the fundraising then an additional 30 days shall be provided to allow for the completion of required fundraising
Licensing Agreement M L R 1023 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement commitments description				On November 17, 2021, Melior I extended the Company’s timeline from 120 days to 180 days from the effective of the MLR-1023 Agreement for the Raise Requirement, by 180 days Adhera is in the process of completing transactions to complete the fundraising then an additional 30 days shall be provided to allow for the completion of required fundraising	if the Company failed to raise $4.0 million within 120 days of the effective date of the agreement then the MLR-1023 Agreement would immediately terminate unless, by 120 days Adhera was in the process of completing transactions to complete the fundraising then an additional 30 days would be provided to allow for the completion of the raise (the “Raise Requirement”)	On August 20, 2021, we as licensee, entered into an exclusive license agreement regarding the development and commercialization of Melior’s MLR-1023 (the “MLR-1023 Agreement”) with Melior Pharmaceuticals I, Inc. (“MP1”). We refer to MP2 and MP1 as “MP” or “Melior”. This second license is for the development and commercialization of MLR-1023, which is being developed as a novel therapeutic for Type 1 diabetes		the Company to raise $4 million (the “Raise Requirement”) to June 16, 2022.
Licensing Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment for licensing agreement		$ 136,921	$ 136,921
Capital raise in additional	$ 500,000	$ 500,000
Licensing Agreement [Member] | Chief Scientific Officer [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Capital raise in additional			$ 500,000